BGI Genomics Co., Ltd. (300676.SZ)

CNY 45.76

(-0.72%)

Market Cap (In CNY)

18.87 Billion

Revenue (In CNY)

4.34 Billion

Net Income (In CNY)

92.9 Million

Avg. Volume

1.88 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
33.0-56.89
PE
-
EPS
-
Beta Value
0.759
ISIN
CNE100003449
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Lijian Zhao
Employee Count
-
Website
https://www.bgi.com
Ipo Date
2017-07-14
Details
BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.